天津中医药大学学报2026，Vol.45Issue(4)：436-443,8.DOI:10.11656/j.issn.1673-9043.2026.04.09
固肠胶囊调控p38MAPK/NF-κB信号通路治疗炎症性肠病机制
Mechanism of Guchang Capsule in treating inflammatory bowel disease by regulating p38MAPK/NF-κB signaling pathway
摘要
Abstract
[Objective]To investigate the therapeutic effect of Guchang Capsule on animal models of inflammatory bowel disease(IBD),and to clarify whether it improves IBD by downregulating long non-coding RNA(lncRNA)THRIL and inhibiting the p38 mitogen-activated protein kinase(p38MAPK)/nuclear factor-κB(NF-κB)signaling pathway.[Methods]A total of 36 male C57BL/6 mice were randomly divided into six groups(6 mice per group):control group,model group,low-dose Guchang Capsule group[500 mg/(kg·d)],medium-dose Guchang Capsule group[1 000 mg/(kg·d)],high-dose Guchang Capsule group[1 500 mg/(kg·d)],and mesalazine group[200 mg/(kg·d)].Except for the control group,all other groups were induced with IBD by drinking 4%dextran sulfate sodium(DSS)aqueous solution for 7 consecutive days.After successful modeling,each administration group received intragastric administration for 10 consecutive days,while the control group and model group received an equal amount of distilled water.The disease activity index(DAI)score of mice in each group was observed.Hematoxylin-eosin(HE)staining was used to observe pathological changes in colon tissue.Enzyme-linked immunosorbent assay(ELISA)was used to detect the levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),interleukin-1β(IL-1β),interleukin-4(IL-4),and interleukin-10(IL-10)in colon tissue.Quantitative real-time polymerase chain reaction(qRT-PCR)was used to detect the expression of lncRNA THRIL.Western blot and immunohistochemistry were used to detect the expression of p38MAPK/NF-κB pathway-related proteins(p-p38MAPK,p38MAPK,p-p65,p65).[Results]Compared with the control group,the model group showed significantly decreased body weight(P<0.05),increased DAI score(P<0.05),increased colon tissue pathological score(P<0.05),increased levels of pro-inflammatory factors TNF-α,IL-1β,and IL-6(P<0.05),decreased levels of anti-inflammatory factors IL-4 and IL-10(P<0.05),increased expression of lncRNA THRIL(P<0.05),and increased protein ratios of p-p38MAPK/p38MAPK and p-p65/p65(P<0.05).Compared with the model group,the medium-dose and high-dose Guchang Capsule groups and the mesalazine group showed significantly increased body weight(P<0.05),decreased DAI score,colon tissue pathological score,and levels of pro-inflammatory factors(TNF-α,IL-1β,IL-6)(P<0.05),increased levels of anti-inflammatory factors(IL-4,IL-10)(P<0.05),and downregulated expression of lncRNA THRILand protein ratios of p-p38MAPK/p38MAPK and p-p65/p65 in colon tissue(P<0.05).[Conclusion]Guchang Capsule can improve IBD symptoms by downregulating lncRNA THRIL and inhibiting the activation of the p38MAPK/NF-κB signaling pathway,thereby reducing intestinal inflammatory responses.关键词
固肠胶囊/炎症性肠病/lncRNA THRIL/p38MAPK/NF-κB信号通路/炎症因子Key words
Guchang Capsule/inflammatory bowel disease/lncRNA THRIL/p38MAPK/NF-κB signaling pathway/inflammatory factor分类
医药卫生引用本文复制引用
王晓红,刘蓉,王红,宋新龙,刘宝山..固肠胶囊调控p38MAPK/NF-κB信号通路治疗炎症性肠病机制[J].天津中医药大学学报,2026,45(4):436-443,8.基金项目
国家自然科学基金项目(81503546) （81503546）
天津市卫生健康委员会天津市中医药重点领域科研项目(2023002) （2023002）
天津市中医药管理局中医中西医结合科研课题项目(2021177). （2021177）
